Angion Announces Participation in Upcoming Investment Conferences
28 févr. 2022 16h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference
04 janv. 2022 16h05 HE
|
Angion Biomedica Corp.
-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE,...
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury
09 déc. 2021 16h05 HE
|
Angion Biomedica Corp.
-- Angion to host a conference call today at 4:30 p.m. EST UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma...
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
12 nov. 2021 07h00 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming Phase 2 Study
05 nov. 2021 00h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion to Participate in Upcoming Investment Conference
02 nov. 2021 01h30 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function
26 oct. 2021 16h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion’s ANG-3777 did not...
Angion to Present Multiple Posters at Kidney Week 2021
18 oct. 2021 16h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis
08 sept. 2021 00h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion to Participate in Upcoming September Investment Conferences
02 sept. 2021 00h20 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...